{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:40:10Z","timestamp":1758948010956,"version":"3.44.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra\u2010rare, potentially life\u2010threatening condition caused by a deficiency of the blood enzyme ADAMTS13. Until now, ADAMTS13 replacement has been achieved with infusions of plasma or plasma\u2010based therapies (PBT). However, the quantitative relationship between ADAMTS13 plasma activity and clinical manifestations is poorly understood. We therefore conducted integrated population pharmacokinetics (PopPK) analysis and exposure\u2013response modeling based on three clinical trials of recombinant ADAMTS13 (rADAMTS13, Takeda Pharmaceuticals U.S.A., Inc.) in patients with cTTP. These aim to assess the clinical benefit of rADAMTS13, which at the proposed dose of 40\u2009IU\/kg provides ADAMTS13 peak levels of approximately 100% of normal levels. The PK model indicated that, besides body weight\u2013based dosing, no further dose adjustment was required based on age or race. The only extrinsic covariates with a significant impact on ADAMTS13 plasma activity levels were dosing interval and treatment type (rADAMTS13 vs. PBT). The correlation between ADAMTS13 plasma activity levels and cTTP manifestations was investigated with three different exposure<jats:bold>\u2013<\/jats:bold>response models. Increasing exposure to ADAMTS13, as measured by average activity over a one\u2010to\u2010two\u2010week period, predicted the probability of disease manifestations, primarily assessed as thrombocytopenia. Model simulations predicted that &gt;90% of patients treated with 40\u2009IU\/kg rADAMTS13 achieve an average ADAMTS13 plasma activity &gt;13% of normal, which was shown to be highly protective against thrombocytopenia (&gt;70% lower hazard). Similar results were observed for protection against elevation of lactate dehydrogenase, a marker of microangiopathic hemolytic anemia. Overall, these results support the use of rADAMTS13 treatment for patients with cTTP.<\/jats:p>","DOI":"10.1002\/cpt.3720","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:54:04Z","timestamp":1749095644000},"page":"813-822","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of <scp>PopPK<\/scp> and E\u2010R Analyses toward Explaining Causal Link Between <scp>ADAMTS13<\/scp> in Recombinant vs. Plasma\u2010Based Therapies and Clinical Effects in <scp>cTTP<\/scp>"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-0899","authenticated-orcid":false,"given":"Munjal","family":"Patel","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-2044","authenticated-orcid":false,"given":"Huijuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Barriere","sequence":"additional","affiliation":[{"name":"Certara USA Inc.  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-7903","authenticated-orcid":false,"given":"Paul","family":"Diderichsen","sequence":"additional","affiliation":[{"name":"Certara USA Inc.  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth","family":"Patwari","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy Z. X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9820-5116","authenticated-orcid":false,"given":"Jean Fran\u00e7ois","family":"Marier","sequence":"additional","affiliation":[{"name":"Certara USA Inc.  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Peyret","sequence":"additional","affiliation":[{"name":"Certara USA Inc.  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda T.","family":"Wang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Mellg\u00e5rd","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenping","family":"Wang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-6844","authenticated-orcid":false,"given":"Indranil","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030536"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.216796"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1813013"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S464365"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-884700"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000065"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.20"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23527"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14345"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314793"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17560"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005024"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103365"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19026"},{"key":"e_1_2_11_15_1","unstructured":"ADZYNMA US prescribing information<https:\/\/www.fda.gov\/media\/173756\/download?attachment>. Accessed October 04 2024."},{"key":"e_1_2_11_16_1","unstructured":"ADZYNMA. European Medicines Agency.Summary of product characteristics<https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adzynma>. Accessed October 04 2024."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788026"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188996"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146148"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05420.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005096"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-122945"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26"},{"key":"e_1_2_11_24_1","unstructured":"US Food and Drug Administration.Population pharmacokinetics: guidance for industry<https:\/\/www.fda.gov\/media\/128793\/download> (2022). Accessed June 01 2024."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.27"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.18"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12797"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09850-2"},{"key":"e_1_2_11_29_1","unstructured":"Columbia University Mailman School of Public Health.Time\u2010to\u2010event data analysis<https:\/\/www.publichealth.columbia.edu\/research\/population\u2010health\u2010methods\/time\u2010event\u2010data\u2010analysis>. Accessed March 01 2024."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217133"},{"key":"e_1_2_11_31_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan.Adzynma Intravenous 1500<https:\/\/www.pmda.go.jp\/files\/000272019.pdf> (2025). Accessed February 26 2025."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:17:06Z","timestamp":1758946626000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cpt.3720"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3720","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"type":"print","value":"0009-9236"},{"type":"electronic","value":"1532-6535"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"2024-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}